BRIEF-Rosetta Genomics up in premarket after tumor study data

NEW YORK Wed Jan 9, 2013 9:00am EST

NEW YORK Jan 9 (Reuters) - Rosetta Genomics Ltd : * Up 19 percent to $5.48 in premarket after tumor study data

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.